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Essentials
• AZD9684 is a potent inhibitor of carboxypeptidase U (CPU, TAFIa, CPB2).
• The effect of AZD9684 on fibrinolysis was investigated in four in vitro systems.
• The CPU system also attenuates fibrinolysis in more advanced hemostatic systems.
• The size of the observed effect on fibrinolysis is dependent on the exact experimental conditions.
Summary. Background: Carboxypeptidase U (CPU, carboxypeptidase B2, activated thrombin-activatable fibrinolysis inhibitor) is a basic carboxypeptidase that attenuates fibrinolysis. This characteristic has raised interest in the scientific community and pharmaceutical industry for the development of inhibitors as profibrinolytic agents. Objectives: Little is known about the contribution of CPU to clot resistance in more advanced hemostatic models, which include blood cells and shear stress. The aim of this study was to evaluate the effects of the CPU system in in vitro systems for fibrinolysis with different grades of complexity. Methods: The contribution of the CPU system was evaluated in the following systems: (i) plasma clot lysis; (ii) rotational thromboelastometry (ROTEM) in whole blood; (iii) front lysis with confocal microscopy in platelet-free and platelet-rich plasma; and (iv) a microfluidic system with whole blood under arterial shear stress. Experiments were carried out in the presence or absence of AZD9684, a specific CPU inhibitor. Results: During plasma clot lysis, addition of AZD9684 resulted in 33% faster lysis. In
Introduction
The fibrinolytic system is responsible for the proteolytic degradation of fibrin clots, and is currently considered to be a major player in the growth, stability and resorption of a thrombus. The enzyme carboxypeptidase U (CPU, carboxypeptidase B2 [CPB2], activated thrombin-activatable fibrinolysis inhibitor) is thought to function as a factor that makes thrombi more resistant to lysis. Consequently, inhibition of CPU activity could be a novel therapeutic strategy for the enhancement of fibrinolysis, and thus could potentially be used as a treatment for arterial thrombosis [1, 2] . CPU is present in the blood as an inactive precursor, procarboxypeptidase U (proCPU, procarboxypeptidase B2, thrombin-activatable fibrinolysis inhibitor). ProCPU is synthesized and secreted by the liver, but it can also be released from platelets upon activation [3] . Through the action of thrombin, the thrombin-thrombomodulin complex, or plasmin, the proCPU zymogen is converted to its active form CPU. CPU attenuates fibrinolysis by removing C-terminal lysine residues from partially degraded fibrin. As such, it counteracts the efficient plasminogen activation that is essential for effective clot breakdown [4] [5] [6] .
Despite the fact that CPU is a potential novel drug target for the treatment of thrombotic diseases, research has been hampered by preanalytical and analytical difficulties associated with the measurement of this unstable enzyme [7] . Recent advances in this field have extended the array of available assays for the direct measurement (activity measurements or antigen-based approaches) and indirect measurement (effects on fibrinolytic velocity, in the presence or absence of selective CPU inhibitors) of CPU [7] [8] [9] . The main limitation of the indirect assays is that the majority of these have been performed on platelet-poor plasma, under static conditions. Such plasma-based systems are undeniably valuable tools with which to investigate fibrinolysis and characterize inhibitors, but do not reflect the in vivo environment completely. Currently, little is known about the contribution of CPU to clot resistance in in vitro models that include other components of the hemostatic system, such as blood cells and shear stress. Consequently, several questions remain to be answered: (i) how the contribution of the CPU system to fibrinolysis is modified in whole blood; and (ii) whether flow conditions and the resulting shear stress can modify the efficacy of the CPU system.
Another approach to obtain insights into the function of CPU is to conduct in vivo studies. In recent years, the role of CPU has been investigated in numerous animal models by using proCPU-deficient mice or by treating animals with CPU inhibitors. Several studies have shown improvement of fibrinolysis upon inhibition/deficiency of the proCPU system [10] [11] [12] [13] [14] [15] [16] [17] [18] . Others have reported contradictory findings, and have shown that CPU inhibition/deficiency has no beneficial effect on recanalization and restoration of the blood flow [15, [19] [20] [21] [22] [23] . Discrepancies in the literature can possibly be explained by differences in the strength/localization of the thrombogenic stimulus, the CPB2 knockout strain, the type of inhibitor, the timing of drug administration, and interspecies differences [24] . In any case, they certainly call for further investigation. Additionally, because of potential differences in gene regulation, which were recently addressed by Boffa et al., caution must be taken when data from animal studies are interpreted and extrapolated to the human situation [25] [26] [27] . Until there is more clarity in this domain, we believe that in vitro CPU research with human clinical samples remains extremely valuable.
In this study, we employed samples collected from different human subjects to evaluate the potential effects of the CPU system on fibrinolysis in four fibrinolytic models, all with different grades of complexity and their own characteristics. AZD9684 -a potent and selective CPU inhibitor -was used as a research tool to abrogate the effect of CPU on fibrinolysis in the different systems.
Materials and methods

AZD9684
AZD9684 is a potent and selective small-molecule CPU inhibitor that was a kind gift from AstraZeneca (M€ olndal, Sweden). The design, synthesis and characterization of this 3-mercapto-propionic acid derivative have been described previously [28, 29] .
Plasma clot lysis assay (CLA)
Blood from five healthy subjects was collected in vacutainers containing 0.129 M trisodium citrate (9 : 1 v/v; Vacuette, Greiner Bio-One, Kremsmu¨nster, Austria). Participants provided informed consent, and the study was approved by the university ethics committee. Samples were centrifuged at 2000 9 g for 15 min to obtain platelet-poor plasma, and aliquots were stored at À 80°C until further analyses were performed. Clots were formed in a 96-well microtiter plate (Nunc, Roskilde, Denmark). In each well, 80 lL of plasma was mixed with 20 lL of tissue-type plasminogen activator (t-PA) (Alteplase, 40 ng mL
À1
). Subsequently, 5 lL of AZD9684 (concentration range: 0-10 lM) and/or 5 lL of rabbit lung thrombomodulin (TM) (0.5 nM; Sekisui Diagnostics, Lexington, MA, USA) were added. Coagulation was initiated by adding 50 lL of CaCl 2 (12.5 nM). Turbidity was spectrophotometrically measured every 30 s at 37°C (Versamax; Molecular Devices; San Jose, CA, USA). Samples intended for proCPU measurements were collected prior to the start of the experiment and immediately after complete lysis. For this purpose, a 12-lL sample was transferred to prechilled aprotinin/PPACK (40 lg mL À1 and 2 lM, respectively) tubes, and immediately placed in iced water (4°C). The proCPU concentration was then determined according to a previously published method [30] . Notably, a plasma proCPU concentration of 1000 U L
with the Bz-o-cyano-Phe-Arg substrate corresponds to a molar concentration of % 200 nmol L
.
CPU generation during in vitro clot lysis
With pooled plasma, the clot lysis procedure described above was repeated for four concentrations of AZD, selected on their capacity to shorten the clot lysis time (CLT) by approximately 0%, 25%, 50%, 75%, and 100%. The concentrations were 0, 37.5, 100, 187
and 5000 nM for the standard CLA, and 0, 109, 209, 400 and 5000 nM for the CLA with 0.5 nM TM. Simultaneously, CPU generation and proCPU consumption were evaluated according to a recently published method [31] .
Thromboelastometry
Rotational thromboelastometry (ROTEM) analysis on fresh citrated whole blood was performed with the ROTEM delta device (Tem Innovations Munich, Germany). A 12-lL mixture of AZD9684, t-PA and/or TM was prepared (0-10 lM, 75 ng mL À1 , and 0.5 nM, respectively). Prior to the start of the analyses, 388 lL of citrated whole blood was added and mixed gently. Three hundred microliters of this mix was then added to a preheated ROTEM cup, and clotting was initiated by the addition of CaCl 2 and tissue factor (TF) (20 lL of STARtem reagent and of 20 lL EXtem reagent). Fibrinolysis was assessed according to the ROTEM software, providing the lysis onset time (LOT) in each condition. The LOT refers to the time that it takes to reduce clot firmness by 15%. For experiments without inhibitor, samples were collected to assess proCPU consumption (as described above).
Front lysis assay
In the front lysis system, the microscopic progression of the lysis front was detected with laser scanning confocal microscopy [32, 33] . In this system, fibrinolytic velocity was evaluated in platelet-free plasma (PFP) and plateletrich plasma (PRP). For the preparation of PFP, citrated whole blood was centrifuged at 1200 9 g for 15 min and subsequently at 10 000 9 g for 5 min. Aliquots were stored at À 80°C until being used. PRP was obtained by centrifugation of citrated whole blood at 120 9 g for 15 min. ; BD Biosciences, Franklin Lakes, NJ, USA) to visualize fibrin fibers and platelets. Clotting was initiated by recalcification (20 nM CaCl 2 ) and addition of TF (diluted 1 : 500 v/v; Dade Innovin, Siemens, Munich, Germany). The mixture was immediately transferred to a front lysis microchamber, as described previously [33] . After 10 min, 20 lL of t-PA with or without AZD9684 (650 ng mL À1 and 5 lM, respectively) was loaded into the chamber, thereby forming an edge with the coagulated plasma front of the chamber. After 10 min, imaging was initiated: every 15s, an optical section of 208 9 208 lm was collected. Progression of the lysis front was examined when complete lysis of the selected surface was obtained. The lysis velocity was calculated with ZEN LITE (blue edition) (Carl Zeiss Microscopy, Jena, Germany), by evaluating the time needed to achieve lysis over a defined length, perpendicular to the lysis front.
Flow chamber system
Principle Recently, a novel flow chamber model was developed that allows real-time analysis of clot formation and lysis in fresh whole blood under arterial conditions [34] . This system offers a unique way to evaluate the in vitro lytic efficacy of drugs, such as CPU inhibitors. The model consists of a two-step process wherein blood is perfused inside a biochip. With fluorescent markers for fibrin and platelets, real-time clot formation is monitored in a first step, and real-time fibrinolysis in a second step.
Chip preparation Vena8 fluoro+ biochip (Cellix Ltd, Dublin, Ireland) channels were coated overnight with a mixture of collagen (Horm; Nycomed, Z€ urich, Switzerland; 50 lg mL
À1
) and TF (diluted 1 : 100 v/v; Dade Innovin, Siemens, Munich, Germany) in a humidified chamber at 4°C. Saturation of free sites with 0.1% bovine serum albumin (BSA) for 30 min at room temperature was followed by washing with flow buffer (10 nM HEPES, 136 nM NaCl, 2.68 nM KCl, 2 nM MgCl 2 , 277 nM glucose, and 0.15% BSA, pH 7.5).
Blood collection and preparation Citrated blood was acquired from 12 healthy subjects by antecubital venipuncture. A first citrated whole blood aliquot was supplemented with DIOC-6 (10 lM) and Hoechst-33342 (8 lg mL À1 ) to label platelets and DNA, respectively, and with Alexa Fluor 647-conjugated human fibrinogen (100 lg mL
) to visualize fibrin. A second blood aliquot from the same individual was treated with rhodamine-6G (125 lM) to visualize new platelet recruitment, and supplemented with t-PA with or without AZD9684 (final concentrations of 3.5 lg mL À1 [53.8 nM] and 5 lM, respectively). Except for fluorescent dyes, which were preincubated for 5 min, all other components were added just prior to the start of each perfusion, and all experiments were conducted within 4 h after sample collection.
Instrumentation Perfusion through a single channel was achieved by negative aspiration of a syringe (1 mL or 2 mL; BD Biosciences, Franklin Lakes, NJ, USA) with an ExiGo microfluidic syringe pump to provide a constant flow rate and shear stress levels mimicking those found in arterial vessels in vivo. Images were continuously recorded with a Zeiss Axio Observer microscope workstation equipped with an ORCA digital CCD camera (Hamamatsu Photonics, Hamamatsu, Japan), and analyzed with ZEN software.
Flow chamber process During the first step, the first whole blood sample was recalcified (CaCl 2 ; final concentration of 5 nM) and immediately perfused over the collagen-coated and TF-coated flow chambers at a shear stress of 67.5 dynes cm À2 or 1500 s À1 for arterial experiments.
Thrombus formation and growth were continuously recorded for 4 min, after which the channel was rinsed for 1 min with flow buffer. Subsequently, successive images covering the channel length were acquired. One thrombus, balanced for fibrin and platelet composition, was selected for continuous imaging during the second perfusion. After setting of the focus on this thrombus, the channel was perfused at the same shear stress as for the first run, with whole blood prepared for the second run. Real-time changes in mean fluorescence of the fibrin-rich network, as well as of the platelets associated with the clot, were recorded, allowing the quantification of fibrinolysis and platelet behavior over a period of 15 min.
Statistical analyses
Data are expressed as the mean AE standard error of the mean. Statistical tests are indicated in each figure, and were performed with GRAPHPAD PRISM, version 7.
Results
Plasma CLA
For clot lysis experiments, a concentration of 40 ng mL À1 t-PA (0.62 nM) was chosen, as complete lysis is achieved within a reasonable timeframe of % 60 min in most healthy individuals [35] . t-PA-mediated lysis of plateletpoor plasma was carried out in five individuals, and resulted in a CLT of 50.5 AE 2.6 min. A representative example is shown in Fig. 1A . In the presence of AZD9684 (5 lM), a CLT of 33.9 AE 1.8 min was found, which corresponds to an acceleration of fibrinolysis by 33% (Fig. 1B) . Addition of TM caused a delay in fibrinolysis, resulting in a significantly prolonged CLT of 74.3 AE 2.9 min. However, when AZD9684 was added to this system, CLT was shortened by 54%, to 34.3 AE 1.6 min. This CLT is similar to the one measured in the experiment without TM, indicating that the retardation of fibrinolysis by TM can be completely attributed to additional activation of the proCPU system. In order to confirm this and gain more insights into the quantity of proCPU that is consumed during the clot lysis experiment, proCPU levels were determined. As shown in Fig. 2A , a significant decrease in proCPU levels was observed after the standard CLA, and this decline was much more pronounced in the presence of TM. (Fig. 2B ) and 200 AE 9 nM in the presence of TM (Fig. 2C) .
CPU generation during plasma clot lysis
In order to evaluate the effects of AZD9684 on CPU generation, four concentrations were selected that resulted in gradual dose-dependent shortening of the CLT. For standard CLA conditions, data are shown in Fig. 3A . As described previously, two CPU activity peaks can be distinguished [31, 35] . The first is the result of activation of proCPU by thrombin-TM, and the second is the result of activation of proCPU by plasmin. When the CPU inhibitor was titrated into the system, the observed dose-dependent effect on CLT was clearly reflected by a systematic reduction in height of the CPU activity peak. In addition, with a higher dose of AZD9684, the second CPU activity peak occurred earlier, owing to faster plasmin formation. The effect of AZD9684 was also evaluated in a system containing TM (Fig. 3B) . This led to a substantial increase in the height of the first CPU activity peak (198 U L À1 versus 14 U L À1 ) and a marked decrease in the proCPU level. The second peak -the plasminmediated CPU peak -remained constant (9.8 U L À1 versus 11.5 U L À1 ), but was dwarfed by the first peak in the graph, owing to the range of the y-axis (upper limit of 200 U L À1 versus 20 U L À1 ), and is therefore shown as an inset in the figure. Again, in the presence of AZD9684, the dose-dependent shortening of the CLT was clearly accompanied by a parallel reduction in the height of the CPU activity peak.
Thromboelastometry
As in the clot lysis experiments, the t-PA dose was optimized to obtain a curve that allowed clear evaluation of fibrinolysis. A dose of 75 ng mL À1 t-PA (1.15 nM) was chosen, and this resulted in a comparable lysis time to the one used to perform the CLA. Once an established protocol was in place, we used the ROTEM assay to evaluate fibrinolysis and involvement of the CPU system in fresh whole blood collected from five healthy individuals. Representative examples of ROTEM curves are shown in Fig. 4A . The LOT was assessed for each condition, and is shown in Fig 4B. Under standard conditions, a mean LOT of 36.6 AE 2.0 min was found. In the presence of AZD9684, clear acceleration of fibrinolysis was observed, as the LOT was reduced by 38% to 22.8 AE 1.7 min. When TM was added to the system, the LOT was prolonged to 49.4 AE 2.5 min, but, again, this effect was completely neutralized when AZD9684 was added, as the LOT was reduced to 22.8 AE 1.8 min. Similarly to clot lysis, proCPU consumption during this process was followed by the collection of samples before the experiment and after complete lysis (Fig. 5A) (Fig. 5C ). 
Front lysis
Representative serial images of the front lysis in PFP and PRP conditions are shown in Fig. 6 (left panel) . The time needed to achieve lysis over a defined length allowed the determination of the fibrinolytic rates shown in Fig. 6 (right panel). In PFP, the inclusion of AZD9684 increased the fibrinolytic rate by 47%, from 9.0 AE 1.4 lm min À1 to 13.5 AE 1.8 lm min À1 (N = 5). In order to investigate the potential effects of platelets on the propagation of the lysis front and inhibition of the CPU system, experiments were repeated on fresh PRP. Similarly to what was observed in PFP, a significantly higher lysis rate was found in the presence of AZD9684, with a 50% increase, from 8.7 AE 1.0 lm min À1 to 12.9 AE 1.3 lm min À1 (N = 10).
Flow chamber
To explore the effects of CPU inhibition under arterial flow, thrombus formation and lysis were monitored with video microscopy in 12 individuals. Thrombus formation was initiated by flushing recalcified whole blood through a TF-precoated and collagen-precoated channel for 4 min. Lysis of a thrombus, balanced for fibrin and platelet content, was obtained in a second perfusion by the perfusion of t-PA-supplemented whole blood, in which AZD9684 was added or omitted to estimate the CPU contribution. An example of a video showing thrombus formation and lysis is available online (Videos S1 and S2). Changes in mean fluorescence intensity over time were measured to assess fibrinolysis, the recruitment of new platelets, or DNA release (Fig. 7) . AZD9684 was found to have no statistically significant effect on t-PA-mediated fibrinolysis of thrombi formed in the microfluidic system under arterial shear stress, although there was a tendency for there to be faster lysis. Simultaneously, platelet accumulation and DNA release were also evaluated. As expected, AZD9684 did not affect platelet recruitment and DNA content. In the presence of TM, however, lysis in the system was significantly inhibited (P = 0.02). Under these conditions, addition of AZD9684 abrogated the effect (Fig. S1 ), indicating the contribution of the CPU system to the delayed clot breakdown.
Discussion
In this study, the effects of the CPU system on the regulation of fibrinolysis were investigated and compared in four different in vitro models of fibrinolysis. Each of these methods has a different degree of complexity, and all have their inherent strengths and limitations. The results for the clot lysis system with 0.5 nM TM. The selected concentrations of AZD9684 were 0, 109, 209, 400 and 5000 nM. All experiments were performed in pooled plasma. It is of note that the range of the y-axis with CPU activities is 10-fold higher for the experiment with TM (0-200 U L À1 ) than for the experiment without TM (0-20 U L À1 ). As a result, the second CPU activity peak is hardly visible for the experiment with TM, and is shown as an inset. CLA, clot lysis assay.
The first method, the CLA, is a relatively simple and robust assay that requires only small volumes of plasma. Several conditions can be evaluated at once, which makes the system suitable for drug screening. Moreover, this system can be modified to monitor the CPU activity during clot formation and fibrinolysis. As it is a turbidimetric method, experiments can only be executed in a plasma environment. Other drawbacks are that the CPU inhibitor and t-PA are incorporated before the clot is formed, and the experiments are performed under static conditions.
The second method used for the evaluation of the CPU system is ROTEM, which has several properties similar to those of the CLA, but uses whole blood. It has a smaller throughput than the CLA, and a sample for proCPU/ CPU measurement can only be collected at the end of the experiment.
In the third method, the front lysis assay, the evolution of the lysis front is detected with confocal microscopy. In this system, t-PA and AZD9684 are not incorporated into the clot, and the spatiotemporal dynamics of fibrinolysis are taken into account. Both features mimic the administration of thrombolytic drugs to patients with acute arterial occlusion to a better extent. A shortcoming of the front lysis system is that, despite the possible inclusion of platelets, the matrix remains plasma.
The flow chamber model in this study allows the evaluation of the effectiveness of fibrinolytic therapies under shear stress in whole blood. Moreover, blood is perfused over a collagen-coated and TF-coated surface, leading to plateletdriven and thrombin-driven thrombus formation, and the system mimics the rupture of a vulnerable atherosclerotic plaque. The current limitations of this system are its complexity, the need for large blood volumes, and the need for analysis within hours after blood collection.
Before proceeding to the discussion on the effect of AZD9684, we need to point out that the concentration of t-PA varies substantially across the different assays. In the current study, t-PA concentrations of 40, 75, 650 and Mean AE standard error of the mean, N = 5. À1 were used for the CLA, ROTEM, the front lysis technique and the flow chamber system, respectively. These concentrations were carefully selected in order to allow an obvious evaluation of the overall fibrinolytic rate within a reasonable timeframe. The degree of fibrinolysis depends on how efficently plasmin is formed, which depends, in its turn, on the timing of t-PA addition and the complexity of the biological matrix. ROTEM and the CLA utilize lower concentrations of t-PA, as incorporation takes place before the initiation of clot formation. This is in contrast to the front lysis technique and flow chamber system, in which t-PA is introduced at the edge of the thrombus and needs to penetrate into the clot. The shear stress present in the latter system will further control the spatial spreading and supply of t-PA to the fibrin network of the thrombus [36] . The presence of blood cells will further modulate the response to plasminogen activators, and explains why higher concentrations of t-PA are present in the ROTEM system than in the CLA, and in the flow chamber system than in the front lysis system. Platelets confer resistance to lysis by promoting clot retraction and releasing plasminogen activator inhibitor-1 and serpin E2 from a-granules [37] . Other blood cells can also profoundly affect the fibrinolytic rate by providing binding sites for t-PA and plasminogen on their surfaces, thereby decreasing fibrinolytic efficiency in favor of pericellular proteolytic activity [37] . Furthermore, when whole blood is used, red blood cells are entrapped in the fibrin network and will hamper diffusion of fibrinolytic proteins in the clot [38] . Another interesting phenomenon that has recently attracted much interest is the formation of extracellular traps by activated neutrophils, resulting in an additional delay in lysis of the thrombus [38] . The effect of the CPU inhibitor AZD9684 was first assessed in the CLA and the ROTEM system. A significantly reduced lysis time was observed when the systems were supplemented with AZD9684. Both methods are well validated and have previously been shown to be sensitive to the effects of other CPU inhibitors [35, [39] [40] [41] [42] . As flexible systems, they allow straightforward adaptation of the experimental conditions. In this study, we found, for both the CLA and ROTEM, a similar: (i) proCPU consumption pattern; (ii) behavior in the presence of TM; and (iii) dose-response relationship for AZD9884.
Altogether, with these findings, there is evidence to conclude that the proCPU system behaves very similarly in the CLA and the ROTEM system. It is of note that the small but consistently higher IC 50 value in the presence of TM can be explained by the fact that AZD9684 is a potent, nanomolar-range, competitive inhibitor. Under these conditions, not only the substrate concentration, but also the enzyme concentration, becomes relevant for the IC 50 measurements (in contrast to K i , which is constant), because there is depletion of the free inhibitor because of binding to the target enzyme. The presence of TM will result in more CPU generation, so more inhibitor will be needed to achieve a half-maximal effect [43] .
We continued this study by assessing the effect of CPU inhibition in the front lysis model. In this system, the dose of t-PA is almost 10 times higher (650 ng mL À1 or 10 nM) than in the CLA and the ROTEM system. t-PA and AZD9684 are added after clot formation. This last point is of clinical relevance, because the development of CPU inhibitors is currently directed towards future implementation in treatment regimens for acute thrombotic diseases, conditions in which thrombus formation has already occurred [1, 36] . In both PFP and PRP the propagation of the lysis front was clearly enhanced in the presence of AZD9684. The present data show that AZD9684 does not need to be incorporated in the thrombus, but accelerates fibrinolysis by locally abrogating the effect of CPU on C-terminal lysine residues of partially degraded fibrin. Despite the marked enhancement of fibrinolysis in the CLA, the ROTEM system, and the front lysis assay, only a small and non-significant tendency for there to be faster lysis was observed for AZD9684 in the flow chamber model. The reason for the lack of clear efficacy remains unclear, but a difference from the other models is that arterial flow is introduced. Fibrin deposition decreases with increasing shear. As a result, arterial shear promotes the formation of platelet-rich thrombi. Additionally, the fibrin network is physically affected and active factors are removed [36] . The combination of these factors possibly changes the relative importance of some reactions, including the CPU pathway, in the fibrinolytic process.
Like any other method, the flow chamber system has limitations, which also need to be considered when the results are interpreted. Because of its complexity -realtime analysis of thrombus formation at a thrombogenic surface, followed by whole blood perfusion for monitoring of fibrinolysis, all under arterial shear stress -substantial variability is introduced, and possibly modest differences in fibrinolysis are not detected on top of t-PA.
A third plausible explanation might be the t-PA concentration itself (3.5 lg mL À1 or 53.8 nM), which was 10-100 times higher than the one used in the other models. This concentration was required to evaluate fibrinolysis in a reasonable timeframe, and mimics mean peak concentrations of alteplase in patients with acute thrombolysis [44] . Despite the fact that more t-PA will eventually lead to more proCPU activation by plasmin, it will also have a large impact on the CPU threshold. Increasing the t-PA concentration increases the threshold, and thus dampens the effect of CPU on lysis time [42] . These assumptions are in accordance with previously published data showing that CPU inhibits fibrinolysis at lower t-PA concentrations, but does not inhibit in vitro thrombolysis at pharmacologically high t-PA concentrations [45] . In any case, the experiments performed in the microfluidic system are intriguing and call for further investigation in future studies. It would be interesting to evaluate the impact of different concentrations of TM, to alter the concentration of t-PA, and to determine whether the impact of CPU on fibrinolysis differs when a venous flow rate is applied. Moreover, fluorescent labeling with an antibody directed towards CPU might provide additional information on the exact localization of CPU in the thrombus. Taken together, these experiments, performed with a range of complementary plasma-based and whole blood in vitro systems, indicate that AZD9684 is able to modulate fibrinolysis in more advanced hemostatic systems. The size of the observed effect is dependent on the exact experimental conditions. It is likely that the efficacy of CPU inhibitors in clinical studies will depend on the exact pathological conditions and comedication. Combined with data from validated animal disease models and human biomarker studies, the results from in vitro assays will play an essential role in the determination of the potential effects of CPU inhibitors in humans. Addendum D. Leenaerts was responsible for study concept and design, blood sampling and measurements, data analysis and interpretation, and drafting of the manuscript. S. Loyau was responsible for study concept and design, blood sampling and measurements, and drafting and critical revision of the manuscript. M. Jandrot-Perrus was responsible for study concept and design, critical revision of the manuscript, and study supervision. D. Hendriks was responsible for study concept and design, critical revision of the manuscript, and study supervision. 
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